In the Kiupel grade scheme, what was the MST for high-grade tumors?

Study for the ACVIM Small Animal Internal Medicine Exam to enhance your veterinary knowledge. Prepare with flashcards and multiple-choice questions, featuring hints and explanations. Ensure success in your exam journey!

Multiple Choice

In the Kiupel grade scheme, what was the MST for high-grade tumors?

Explanation:
In this question the key idea is how the Kiupel two-tier grading system for canine lymphoma relates histologic grade to prognosis. Kiupel’s scheme divides lymphomas into low-grade and high-grade categories based on specific histopathologic features, and this grading correlates with how aggressively the disease behaves and how long dogs tend to survive. High-grade lymphomas show more aggressive biology—rapid cell turnover, greater dissemination, and poorer response to therapy—so the median survival time tends to be shorter. The value most consistently reported for high-grade tumors under the Kiupel scheme is about 120 days, reflecting that poorer prognosis compared with low-grade disease. So, when you see a figure around 120 days for high-grade tumors in the Kiupel framework, it aligns with the expected outcome for this more aggressive category.

In this question the key idea is how the Kiupel two-tier grading system for canine lymphoma relates histologic grade to prognosis. Kiupel’s scheme divides lymphomas into low-grade and high-grade categories based on specific histopathologic features, and this grading correlates with how aggressively the disease behaves and how long dogs tend to survive.

High-grade lymphomas show more aggressive biology—rapid cell turnover, greater dissemination, and poorer response to therapy—so the median survival time tends to be shorter. The value most consistently reported for high-grade tumors under the Kiupel scheme is about 120 days, reflecting that poorer prognosis compared with low-grade disease.

So, when you see a figure around 120 days for high-grade tumors in the Kiupel framework, it aligns with the expected outcome for this more aggressive category.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy